<bill session="117" type="h" number="7473" updated="2023-05-11T15:46:24Z">
  <state datetime="2022-04-07">REFERRED</state>
  <status>
    <introduced datetime="2022-04-07"/>
  </status>
  <introduced datetime="2022-04-07"/>
  <titles>
    <title type="display">Generic Substitution Noninterference Act</title>
    <title type="short" as="introduced">Generic Substitution Noninterference Act</title>
    <title type="official" as="introduced">To prohibit pharmaceutical manufacturers from interfering with therapeutically equivalent or interchangeable substitution decisions by health care providers to limit competition from a generic drug or biosimilar biological product, and for other purposes.</title>
  </titles>
  <sponsor bioguide_id="M000087"/>
  <cosponsors>
    <cosponsor bioguide_id="C001084" joined="2022-04-07"/>
    <cosponsor bioguide_id="D000623" joined="2022-04-07"/>
    <cosponsor bioguide_id="N000002" joined="2022-04-07"/>
    <cosponsor bioguide_id="P000618" joined="2022-04-07"/>
    <cosponsor bioguide_id="R000606" joined="2022-04-07"/>
    <cosponsor bioguide_id="S001145" joined="2022-04-07"/>
    <cosponsor bioguide_id="W000800" joined="2022-04-07"/>
  </cosponsors>
  <actions>
    <action datetime="2022-04-07">
      <text>Introduced in House</text>
    </action>
    <action datetime="2022-04-07" state="REFERRED">
      <text>Referred to the House Committee on the Judiciary.</text>
    </action>
    <action datetime="2022-11-01">
      <text>Referred to the Subcommittee on Antitrust, Commercial, and Administrative Law.</text>
    </action>
  </actions>
  <committees>
    <committee code="HSJU" name="House Judiciary" subcommittee="" activity="Referral"/>
    <committee code="HSJU05" name="House Judiciary" subcommittee="Administrative State, Regulatory Reform, and Antitrust" activity="Referral"/>
  </committees>
  <relatedbills/>
  <subjects>
    <term name="Health"/>
  </subjects>
  <amendments/>
  <summary date="2022-09-20T17:20:15Z" status="Introduced in House">Generic Substitution Noninterference Act

This bill prohibits drug manufacturers from helping or directing health care providers to limit prescriptions to brand-name drugs when generic versions are available. The Federal Trade Commission and states may enforce this bill through civil actions.</summary>
</bill>
